Ablukast
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H34O8 |
Molar mass | 498.572 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease.[1][2] It reached Phase III clinical trials, but development was discontinued in 1996.[2]
References
- ^ Rosenbach T, Csatò M, Czarnetzki BM (January 1988). "Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis". The British Journal of Dermatology. 118 (1): 1–6. doi:10.1111/j.1365-2133.1988.tb01743.x. PMID 2829957. S2CID 1164113.
- ^ a b "Ablukast". Adis Insight.
External links
- Media related to Ablukast at Wikimedia Commons
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemical pages without DrugBank identifier
- Commons category link is on Wikidata
- Leukotriene antagonists
- Chromanes
- Piceol ethers
- Phenols
- Resorcinol ethers
- Cyclic ethers
- Abandoned drugs
- All stub articles
- Dermatologic drug stubs